The wireless device will connect to any data-capable glucometer to automatically communicate blood glucose readings to a secure online location, which means either you the patient or perhaps a doctor or healthcare facility might be receiving the readings. These are the folks that make the implanted chip which had slowly died until the recent discussions with Siemens. The press release says it can go back to the “payers” but not over my dead body would I want that at all as with the current structure and business plans of health insurance companies they would use algorithmic formulas taken from such readings and use it against paying claims, that’s how I see it, being a data person and one more good reason to again revisit single payer options.
PositiveID The “Chip” People are Back-an Agreement with Siemens To Expand Wireless Body Monitoring With A Chip Implant
This device is not a chip and again collects data so again, going to the patient PHR, whereby they could “choose” to share the data would be great. Again if we didn’t have the poor ethics and use of data to algorithmically score and deny payment items that we have now, it wouldn’t perhaps be such a bad idea, but still a PHR in the middle is the way to go to give the patient the option. I say this too about the pill bottle and all other types of devices that are coming out, keep the patient in control of their data so we don’t end up with the “big brother” effect here. Wireless devices can be a big help and assistance if implementation and the human element is maintained. BD
DELRAY BEACH, Fla., March 9, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or the "Company") (Nasdaq:PSID) announced today that it has completed the development of its iglucose™ wireless communication system for real-time diabetes management. iglucose is a wireless device that connects to any data-capable glucometer to automatically communicate blood glucose readings to a secure online database. iglucose provides next generation, real-time data to improve diabetes management and help ensure patient compliance, data accuracy and insurance reimbursement. The Company expects to submit its application to the FDA for 510(k) clearance during the second quarter.
The iglucose system, a stand-alone, self-contained unit that operates without the use of a cell phone or personal computer, automatically queries data-capable glucometers for blood glucose readings and sends that data via wireless machine-to-machine (M2M) technology to an online database. At the patient's discretion, blood glucose data can also be forwarded to physicians and caregivers at predetermined intervals.
Scott R. Silverman, Chairman and CEO of PositiveID, said, "We are very pleased that in one year's time, we have taken a bulky, bench-top device the size of a shoebox, and made it into a universal, wireless communication device the size of a smart phone that is ready to be submitted to the FDA for 510(k) clearance. We have lined up important marketing partners and believe that when commercialized, iglucose will fundamentally impact diabetes management by providing real-time glucose readings to loved ones, healthcare professionals and payers via wireless technology."
According to a November 2009 study by researchers at the University of Chicago published in the journal Diabetes Care, the number of diabetics in the U.S., which currently stands at 23.7 million, may almost double in 25 years, and the annual cost of treating them may triple to $336 billion.
About PositiveID Corporation
PositiveID Corporation develops and markets healthcare and information management products through its diagnostic devices and identification technologies, and its proprietary disease management tools. PositiveID's implantable healthcare devices and external hardware and software products are designed to communicate wirelessly to improve healthcare and the patient's quality of life. For more information on PositiveID, please visit www.PositiveIDCorp.com.